Fig. 4
PFS subgroup analysis by number of treatment line. Kaplan–Meier curves of PFS in patients who received fulvestrant and trastuzumab combination therapy as ≤3 line treatment or > 3 line treatment
Fig. 4 | BMC Cancer
PFS subgroup analysis by number of treatment line. Kaplan–Meier curves of PFS in patients who received fulvestrant and trastuzumab combination therapy as ≤3 line treatment or > 3 line treatment